Parkinson syndrome: Iatrogenic causes, iatrogenic side effects;PARKINSON-SYNDROM: IATROGENE URSACHEN, IATROGENE BEHANDLUNGSFOLGEN

Schweizerische Medizinische Wochenschrift

Volumn 126, Issue 13, 1996, Pages 522-527

  Burgunder, J M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIEMETIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVODOPA; LITHIUM; LOXAPINE; METHYLDOPA; METOCLOPRAMIDE; MOLINDONE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; RESERPINE; SELEGILINE; TACRINE; THIOXANTHENE DERIVATIVE; VALPROIC ACID;

CONFERENCE PAPER; DYSKINESIA; DYSTONIA; HALLUCINATION; HUMAN; IATROGENIC DISEASE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PSYCHOSIS; TREMOR; VERTIGO;

ANTIPARKINSON AGENTS; DRUG THERAPY; DYSKINESIA, DRUG-INDUCED; HUMANS; MEDICATION ERRORS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY;

EID: 0029878691     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
2. Quinn N: Parkinsonism - recognition and differential diagnosis. Br Med J 1995; 310: 447-452.
3. Friedman JH: Drug-induced Parkinsonism. In: Lang AE and Weinder WJ (Hrsg): Drug-induced movement disorders. New York: Futura Publishing Co., 1992: 41-83.
4. Lehman HE, Hanrahan GE: Chlorpromazine: new inhibiting agent for psychomotor excitement and manic states. Arch Neurol Psychiatry 1954; 71: 227.
5. Ayd FJ Jr: A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054-1060.
6. Korczyn AD, Goldberg GJ: Extrapyramidal effects of neuroleptics. J Neurol Neurosurg Psychiatry 1976; 39: 866-869.
7. Moleman P, Janzen G, v Bargen BA, Kappers EJ, Pepplinkhuizen L et al.: Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol. Am J Psychiatry 1986; 143: 232-234.
8. Metzer WS, Newton JE, Steele RW, Claybrook M, Paige SR et al.: HLA antigens in drug-induced parkinsonism. Mov Disord 1989; 4: 121-128.
9. Miller LG, Jankovic J: Metoclopramid-induced movement disorders. Arch Intern Med 1989; 149: 2486-2492.
10. Baldessarini RJ, Frankenburg FR: Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324: 746-754.
11. Crowley TJ, Hoehn MM, Rutledge CD, Stallings MA, Heaton RK et al.: Dopamin excretion and vulnerability to drug-induced parkinsonism. Arch Gen Psychiatry 1978; 35: 97-104.
12. Werner EG, Olanow CW: Parkinsonism and amiodarone therapy. Ann Neurol 1989; 25: 630-632.
13. Garcia Albea E, Jimenez FJ, Peralta L, Ayuso PL, Valdivia F et al.: Parkinsonism unmasked by verapamil. Clin Neuropharmacol 1993; 16: 263-265.
14. Mangone CA, Herskovits E: Extra pyramidal and depressive reactions wih flunarizine and cinnarizine. J Neurol Neurosurg Psychiatry 1989; 52: 288-289.
15. Barochovsky O, Bradford HF: Development of transmitter-releasing capacity in neuron-enriched tissue cultures. J Neurochem 1987; 48: 787-797.
16. de Yébenes MJG, Casarejos MJ, Mena MA, de Yébenes JG: Effects of calcium antagonists on dopamine-rich human neuroblastoma cells. Mov Dis 1992; 7 (S1): 61.
17. 3H]spiperone binding to D-2 dopamine receptors in striatal homogenates by organic calcium-channel antagonists and pouvaient cations. Eur J Pharmacol 1985; 106: 133-139.
18. Alvarez Gomez MJ, Vaamonde J, Narbona J, Barao M, Barona P et al.: Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol 1993; 16: 451-455.
19. Micheli FE, Fernandez Pardal MM, Giannaula R, Gatto M, Paradiso G et al.: Movement disorders and depression due to flunarizine and cinnarizine. Mov Dis 1989; 4: 139-146.
20. Assal JP, Albeanu A, Riesch BP, Vaucher J: Coût de la formation du patient atteint d'un diabète sucré. Effects sur la préventíon des amputations. Diabète Métab 1993; 19 (Suppl. 5): 491-495.
21. Quinn N: Drug treatment of Parkinson's disease. Br Med J 1995; 310: 575-579.
22. Factor SA, Singer C: Neuroleptic malignant syndrome. In: Lang AE, Weiner WJ (Hrsg): Drug-induced movement disorders. New York: Futura Publishing Co., 1992: 199-230.